Tag: Windtree Therapeutics

Windtree Presents New Istaroxime Phase 2b Study Analysis at the American College of Cardiology (ACC) Congress

Efficacy of 24 Hour Istaroxime Infusion is Similar Between Caucasian and Asian Patients Hospitalized for Acute Heart Failure WARRINGTON, Pa., April 6, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, […]

Windtree Enters into Agreement with Lee’s Pharmaceutical for Non-Dilutive Funding of the Continued Development of AEROSURF®

WARRINGTON, Pa., March 31, 2020 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, announces it has entered into a binding term sheet (the “Term Sheet”) with Lee’s Pharmaceutical Holdings (HK) Ltd (“Lee’s”) […]

Windtree Therapeutics Completes $26.4 Million Private Placement

WARRINGTON, Pa., Dec. 9, 2019 /PRNewswire/ — Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device technologies to address acute cardiovascular and pulmonary diseases, today announced that it has completed a $26.4 million private placement of common stock and warrants. In connection with this offering, […]